LOS ANGELES, Oct. 03, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Sequans Communications S.A. (“Sequans” or the “Company”) (NYSE:SQNS) regarding possible violations of federal securities laws from April 29, 2016 through July 31, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Sequans shares during the Class Period should contact the firm prior to the October 10, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, during the Class Period, Sequans made false and/or misleading statements, and/or failed to disclose, that the Company was improperly recognizing revenue, and as a result, its public statements were materially false and misleading at all relevant times. On August 1, 2017, Sequans announced that its revenue in the second quarter was negatively affected by a product return from an early 2016 sale related to the tablet business. Following this news, Sequans’ stock price dropped materially, which caused investors harm.
Lundin Law PC was created by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.
This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/


Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Anta Sports Expands Global Footprint With Strategic Puma Stake
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Washington Post Publisher Will Lewis Steps Down After Layoffs
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 



